Appendix B: Panel Roster and Financial Disclosures
Invasive Mycoses
Member | Institution | Financial Disclosure | |
---|---|---|---|
Company | Relationship | ||
Neil Ampel | University of Arizona, College of Medicine | None | N/A |
David Boulware | University of Minnesota Medical School |
Appili Therapeutics Matinas BioPharma |
Research Support (paid to institution) |
Richard Hamill | Baylor College of Medicine | None | N/A |
Carol Kauffman* | University of Michigan Medical School and Veterans Affairs Ann Arbor Healthcare System |
Cidara Laboratoires SMB S.A. |
Data Safety Monitoring Board |
Marisa Miceli | University of Michigan Medical School |
SCYNEXIS F2G Mayne |
Research Support (paid to institution) |
SCYNEXIS | Data Safety Monitoring Board | ||
Astellas Pharma | Consulting | ||
Peter Pappas | The University of Alabama at Birmingham, School of Medicine |
Astellas Pharma Merck |
Research Support (paid to institution) |
Cidara Therapeutics | Scientific Advisory Board | ||
SCYNEXIS | Advisory Board (Research Support) | ||
John Perfect | Duke University, School of Medicine | Pfizer | Scientific Advisory Board |
Key: * = Section Group Lead Note: Members are required to update disclosures annually and to notify guideline staff of any relevant changes in status during the interim. |
Download Guidelines
- Section OnlyPDF (276.93 KB)
- Full GuidelinePDF (5.45 MB)
- Tables OnlyPDF (886.23 KB)